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Dopamine D1 and D2 receptors differ with respect to patterns of regional brain 
distribution and behavioral effects. Preclinical work suggests that D1 agonists enhance 
working memory, but the absence of selective D1 agonists has constrained using this 
approach in humans. This study examines working memory performance in mild traumatic 
brain injury (MTBI) patients when given pergolide, a mixed D1/D2 agonist, compared to 
bromocriptine, a selective D2 agonist. 15 individuals were studied one month after MTBI 
and compared to 17 healthy controls. At separate visits participants were administered 
1.25mg bromocriptine or 0.05mg pergolide prior to functional MRI using a working 
memory task (visual-verbal n-back). Results indicated a significant group-by-drug 
interaction for mean performance across n-back task conditions, where the MTBI group 
showed better performance on pergolide relative to bromocriptine, while controls showed 
the opposite pattern. There was also a significant effect of diagnosis, where MTBI patients 
performed worse than controls, particularly while on bromocriptine, as shown in our prior 
work. Functional MRI activation during the most challenging task condition (3-back>0-back 
contrast) showed a significant group-by-drug interaction, with the MTBI group showing 
increased activation relative to controls in working memory circuitry while on pergolide, 
including in the left inferior frontal gyrus. Across participants there was a positive 
correlation between change in activation in this region and change in performance 
between drug conditions. Results suggest that activation of the D1 receptor may improve 
working memory performance after MTBI. This has implications for development of 
pharmacologic strategies to treat cognitive deficits after MTBI.  

























































































































































































































































































Most individuals recover well from mild traumatic brain injury (MTBI), but a subset of 
patients evidence persistent cognitive impairment, including measurable deficits in speed 
of information processing, attention, and executive functioning.1 Executive functioning 
includes working memory (WM), the ability to retain information and manipulate it while 
receiving new information.2, 3 The importance of the prefrontal cortex (PFC) in cognitive 
functioning, including WM, is well documented.4, 5 The PFC is exquisitely sensitive to 
catecholamine levels, which interact with local receptors in an inverted-U dose-response 
fashion where both excess and insufficient neurotransmitter can impair WM function.6-9 
TBI is thought to generate catecholamine imbalances,10-12 and dysregulation of PFC 
circuitry by disruption of catecholamine levels has been a longstanding hypothesis for 
post-TBI cognitive deficits.10, 11, 13 While PFC catecholamine pathways can be challenging to 
explore directly, pharmaceutical agonists may permit differentiation of signaling pathways 
and allow comparison of differential treatment response in the healthy versus TBI brain. 
Furthermore, modulation of catecholamine levels in PFC by pharmaceutical agents is a 
promising but unrefined treatment for post-TBI cognitive sequelae.14-17 
The PFC contains both D1 and D2 receptors, with D1 being predominant.18 Current 
hypotheses suggest D1 receptors mediate neural signaling by limiting response to less 
preferred stimuli, therefore acting as PFC signaling gates, while D2 receptors increase 
speed and strength of signal response and are less critical to PFC function than D1 
receptors.7 Bromocriptine is a powerful D2 agonist shown to improve WM performance in 
both healthy human and animal populations.19, 20 In our previous work, however, TBI 
patients showed poorer WM performance when administered bromocriptine relative to 
placebo, and displayed increased functional MRI (fMRI) activation outside of the task-
specific region of interest.19 This suggests an altered signaling environment in TBI brains,21 
and indicates that bromocriptine may impair the ability to deactivate regions beyond task-
related circuitry, potentially requiring compensatory activation to maintain a similar level 
of WM performance as healthy controls.  
Pergolide is a mixed D1/D2 agonist. In the absence of selective D1 agonists approved for 
human use, it offers an opportunity to characterize the role of D1 receptors when 























































































































































































































































































pergolide’s effects in TBI patients; however, the high concentration of D1 receptors in the 
PFC suggests it could be beneficial in improving cognitive deficits after TBI. Pergolide has 
not previously been systematically studied for effects on cognition after TBI, though 
several studies have been conducted in healthy controls.22-27 For example, Muller et al.22 
found that pergolide, but not bromocriptine, facilitated visuospatial WM performance. 
Kimberg and D’Esposito23 found improved performance on delayed response tasks after a 
single dose of pergolide for individuals with higher verbal WM capacity, as well as altered 
WM-related activation.24 In contrast, Bartholomeusz et al.25 found no effect of pergolide or 
bromocriptine on object WM. In clinical populations, both pergolide and pramipexole 
(administered for at least one month to separate groups of patients) led to improved WM 
performance in patients with Parkinson’s disease, but only for those with lower WM 
capacity.28 Four weeks of pergolide treatment was also associated with improvements in 
visuospatial WM, executive functioning, and verbal learning and memory in patients with 
schizotypal personality disorder.29 In the only study in TBI, McHenry30 examined the effects 
of pergolide on language function in a single patient after severe TBI, and found no 
beneficial effects. Comparing bromocriptine and pergolide effects in individuals with TBI 
could shed light on the relative role of D1 versus D2 signaling in WM deficits and potential 
treatment after TBI, and could add further insight into the functioning of D1 and D2 
receptors in the PFC. We hypothesized that pergolide would improve WM in TBI patients 
and show related alterations in brain activation on fMRI.  
Materials and Methods 
This was a prospective, placebo-controlled, double-blind study of patients with MTBI 
referred to a Level 1 Trauma Center.  
Participants: 15 MTBI patients were studied approximately one month after injury and 
compared to 17 healthy controls. MTBI diagnosis was established using American Congress 
of Rehabilitation Medicine criteria.31 Patients were excluded if they had a history of other 
neurologic disorders, significant systemic medical illness, or current DSM-IV Axis I 
diagnosis, based on the Structured Clinical Interview for DSM-IV.32 Healthy controls were 
recruited through advertisements and were screened for neurologic, medical, or any past 
or current psychiatric illness. Written informed consent was obtained, and all study 























































































































































































































































































Study Protocol: We have previously published our findings regarding bromocriptine19 and 
guanfacine33 relative to placebo. Here we compare WM performance and fMRI activation 
patterns in a subset of participants in19 who received both bromocriptine and pergolide. In 
brief, participants were studied on three occasions roughly one week apart as part of a 
larger study in which each individual received placebo, bromocriptine, and either 
guanfacine or pergolide in a randomized, counterbalanced order. Order of 
neuropsychological and fMRI task administration, using alternate forms when available, 
was also counterbalanced.  
Participants had a line for intravenous access placed and had blood samples drawn 
(baseline and 1, 2, 3, and 4 hours after medication/placebo ingestion) to determine serial 
serum prolactin levels. Blood was collected in serum separator tubes and immediately sent 
to the lab. After clotting, samples were centrifuged at 3000 rpm and then immediately 
frozen and stored at -80oC until ready for assay. The prolactin assay is based on a solid-
phase, two-site chemiluminescent immunometric format performed on the Immulite 
analyzer (Diagnostic Products Corporation, Los Angeles, CA). Dopamine agonists result in 
decreased release of prolactin, which serves as an indicator of central dopaminergic effect. 
Participants ingested identical-appearing capsules containing placebo, 1.25mg 
bromocriptine, or 0.05mg pergolide. Participants and staff were blind to medication 
condition, and drug and placebo presentation order was counterbalanced. MRI scanning 
was conducted 2.5-3 hours after drug or placebo ingestion, and neuropsychological testing 
was conducted after scan completion.  
Imaging: All scans were acquired using the same GE Horizon 1.5T LX scanner. A gradient 
echo, echo-planar sequence was used to provide whole brain coverage: TR=2500ms, 
TE=40ms, FOV=24cm, NEX=1, 29 5mm thick sagittal slices with no skip, yielding a 64x64 
matrix with 3.75mm2 in-plane resolution. Participants were positioned in the scanner using 
laser alignment beams, and a non-magnetic deformable foam head holder to stabilize 
head position. Noise level was attenuated with specialized headphones (Resonance 
Technology, Van Nuys, CA). Stimuli for the n-back task were programmed in Presentation 
(Neurobehavioral Systems, Inc., Albany, CA) and presented visually through an MRI 
























































































































































































































































































fMRI Task: Participants performed a visual-verbal n-back task presented in a four-
condition, blocked design with variable processing load requirements (0-, 1-, 2-, and 3-back 
conditions). Each n-back condition was presented in 27-second epochs preceded by three 
seconds of instruction (e.g., "the match is D" or "the match is one back"). Each task 
condition was presented three times in pseudo-random order (12 epochs total). 
Participants viewed a string of consonant letters (except L, W, and Y) presented at a rate of 
one every three seconds. For each stimulus participants used a button press device 
(Photon Control, Burnaby, BC) to signify whether the current letter was a match (i.e., was 
the same as the designated target or the letter presented 1, 2, or 3 “back” in the 
sequence, depending on the condition instructions) or was a non-match. The number of 
correct and incorrect responses was recorded, along with reaction times. During each 
epoch there was a possibility of 2 or 3 matches and the number of matches was 
counterbalanced within and across conditions. In addition, non-target recurrences were 
presented as foils (e.g., a 2-back match during the 3-back condition). Participants 
rehearsed a practice version of the task prior to the scan to ensure comprehension of task 
demands. 
Scan Preprocessing: Preprocessing in SPM (Wellcome Department of Cognitive Neurology, 
University College, London, UK) included spatial realignment using a six parameter model 
to remove motion-related signal change, normalization into standardized Montreal 
Neurological Institute atlas space, resampling to 2mm3 isotropic voxels, and smoothing to 
a full width half maximum of 8mm.  
Clinical and Neuropsychological Assessment: Participants completed a neuropsychological 
test battery that assessed level of general intellectual functioning (Wide Range 
Achievement Test-3 (WRAT-3), Reading subtest;34 Wechsler Adult Intelligence Scale-III 
(WAIS-III), Block Design subtest35), verbal episodic memory (California Verbal Learning Test 
(CVLT)36 or CVLT-II37), psychomotor speed (WAIS-III, Digit Symbol-Coding subtest35) and 
WM, executive, and attentional functioning (Trail Making Test, Parts A and B38 or Delis-
Kaplan Executive Function System (D-KEFS), Trail Making Test Conditions 2 and 4;39 D-KEFS 
Color-Word Interference Test;39 Controlled Oral Word Association Test;40, 41 Paced 
























































































































































































































































































Statistical Analyses: Demographics and Cognitive Measures: Demographic variables were 
compared with analysis of variance (ANOVA) or chi-square statistics, as appropriate. In-
scanner n-back performance and neuropsychological variables were analyzed with 
repeated measures analysis of covariance (ANCOVA) using maximum likelihood estimation 
to test effects of drug condition (bromocriptine versus pergolide), diagnosis (MTBI versus 
control), and their interaction, controlling for order of drug administration, age, and years 
of education. For the n-back task, performance was calculated as target accuracy adjusted 
for guessing for each task condition. Additionally, means were calculated across all 
conditions (mean-back), and across all conditions without 0-back. For neuropsychological 
test data, raw or standard scores were used as indicated, with the exception of Trail 
Making. Because the version of the test changed during the study, raw scores for Trails A 
and B and D-KEFS conditions 2 and 4 were z-transformed using the control group means in 
the placebo condition, with z-scores utilized for group comparisons. 
Serum Prolactin Levels: Repeated measures ANCOVA was also used to assess the effect of 
bromocriptine and pergolide on serum prolactin levels. A logarithmic transformation was 
applied to the dependent variables after inspection of initial plots of the data. A random 
interaction effect was included between individual and treatment period in the crossover 
design. A fixed effect was included for TBI status and the interaction between TBI status 
and treatment. All models were fit using Proc Mixed and the heterogenous autoregressive 
covariance structure in SAS (SAS Institute, Cary, NC).  
fMRI Analyses: fMRI analyses included statistical parametric mapping on a voxel-by-voxel 
basis, using a general linear model approach44 as implemented in SPM. Smoothed, 
normalized scans for all individuals were entered into the model, and contrast images 
comparing pairs of the WM processing load conditions were created for each individual. 
Given our prior work with this task, analyses focused on the most challenging condition 
(i.e., 3-back>0-back contrast). These contrast images were then used for the second level 
multi-subject/between-group random effects analyses. The random effects procedure 
performs a mixed model analysis to account for both random effects (scan) and fixed 
effects (task condition).45  
Random effects analyses were conducted using ANCOVA to construct contrast maps of 























































































































































































































































































model in SPM). Comparisons were conducted within an omnibus group- (two independent 
levels: MTBI, control) by-drug (two non-independent levels: bromocriptine, pergolide) 
ANCOVA, covarying for order of drug administration, age, and years of education. The 
design matrix therefore included both drug conditions for both groups, accounting for the 
repeated measures nature of the drug factor (i.e., the matrix included four columns, one 
for each group on each drug). The critical significance threshold (pcrit) was set to 0.01, and 
the main effect of the contrast of interest (i.e., 3-back>0-back; p=0.05) for both groups at 
both visits was included in the design matrix as an explicit mask (Figure 2A). Given the 
constraints of the sample size, only clusters of activated voxels with cluster-level 
puncorrected<0.05 were considered. Effect sizes for significant clusters were calculated using 
Cohen’s D. Two-tailed correlations between brain activation and task performance were 
performed in SPSS.   
Results 
Demographics: Sample characteristics are summarized in Table 1. There were no 
significant group differences for age, sex, or WRAT-3 Reading or WAIS-III Block Design 
scores (good estimates of premorbid verbal and nonverbal intellectual ability, 
respectively). Although completed years of education was slightly higher in the control 
than MTBI group (16.0 versus 14.1 years; p=0.02), this was accounted for by the fact that 
several MTBI participants were students at the time of study participation and had not 
attained their final educational achievement; parental education did not differ between 
groups. MTBI participants entered the protocol a mean of 38.7 (+14.0) days after injury 
(range: 19-69). 10 of 15 participants had a definite loss of consciousness with a mean 
duration of 7.1 (+13.4) minutes. The MTBI group had a mean Glasgow Coma Scale score 
of 14.7 (+0.7) and mean posttraumatic amnesia duration of 8.5 (+9.9) hours. The protocol 
was well tolerated by both groups. 
Serum Prolactin: Figure 1 shows serum prolactin levels over time for participants while on 
bromocriptine, pergolide, and placebo. Blunting of serum prolactin levels while on active 
medication (i.e., bromocriptine and pergolide) started at about 2-2.5 hours after ingestion 
and lasted for at least 5 hours after ingestion; this encompassed the time when 
participants were undergoing fMRI and neuropsychological testing and confirmed that 























































































































































































































































































showed contrasts of the effects of drug (bromocriptine and pergolide) versus placebo 
were statistically significant (p<0.001) and were not appreciably different between each 
other (p=0.11) or between the TBI and control groups (p=0.56). 
Neuropsychological Measures: In general, both groups performed comparably whether 
they were taking pergolide or bromocriptine, with no significant effects of diagnosis or 
drug across tasks, with one exception. For the Trail Making Test, Trial 2/Trails A condition, 
there was a main effect of drug, with both the MTBI and healthy control groups 
performing better when on pergolide than when on bromocriptine (p=0.03; Table 2).  
In-scanner WM Performance: Similar to the neuropsychological measures, there were 
generally no significant within-group differences for pergolide relative to bromocriptine, 
with the exception of the 0-back condition, where the MTBI group showed better 
performance on pergolide than bromocriptine (p=0.04; Table 2). Between-group 
comparisons showed that when on bromocriptine the MTBI group showed significantly 
poorer performance than controls for 0-back, 3-back, mean-back, and mean-back 
excluding 0-back (all p<0.05). There was a significant main effect of group for mean-back 
score, with controls performing better than those with MTBI (p=0.03). There were 
significant interaction effects for 0-back, 3-back, and mean-back scores, wherein the MTBI 
group performed better when taking pergolide than bromocriptine, while controls showed 
the opposite pattern. That is, while the MTBI group consistently performed worse than the 
control group across n-back conditions, pergolide was associated with better n-back 
performance for the MTBI group relative to bromocriptine, whereas controls performed 
less well on pergolide relative to bromocriptine. 
fMRI Results: Both groups showed the expected pattern of robust bilateral frontoparietal 
activation during WM processing while performing the 3-back task regardless of drug 
condition. A significant group-by-drug interaction was found, wherein the MTBI group 
showed increased activation relative to healthy controls in WM circuitry including 
bilateral frontal and parietal regions while on pergolide relative to bromocriptine (Figure 
2B, Table 3). There were no regions in which controls showed significantly increased 
activation relative to the MTBI group on pergolide relative to bromocriptine. Review of 























































































































































































































































































(Cohen’s D generally 0.7 to 1.1; Table 3), although it should be noted that confidence 
intervals are relatively wide given the modest sample size.   
Examination of the clusters found to be significant in this interaction showed that across 
all participants there was a positive correlation between change in activation in the left 
inferior frontal gyrus (Brodmann Area 46) cluster and change in performance between 
drug conditions (r=0.43, p=0.01; Figure 2C), such that increased 3-back performance on 
pergolide relative to bromocriptine was associated with increased left inferior frontal 
gyrus activation.  
Discussion 
The results of this study provide additional evidence of differential alterations in 
dopaminergic systems that impact WM performance and brain activation one month after 
MTBI. Because D1 and D2 receptors differ with respect to patterns of regional brain 
distribution and effect, we compared two pharmacological agents with different dopamine 
profiles. We have previously shown that MTBI patients showed poorer WM performance 
on bromocriptine, a selective D2 agonist, relative to placebo. In addition, healthy controls 
showed greater activation in frontoparietal WM circuitry relative to MTBI patients on 
bromocriptine, while patients showed greater activation outside WM circuitry.19 The 
literature suggests that D1 stimulation enhances WM, and that D1 receptors may play a 
more important role in WM than D2 receptors.46 Furthermore, there is relatively greater 
D1 than D2 receptor density in the PFC, a region critical to effective WM functioning. In the 
current study we therefore examined the same participants to compare performance and 
brain activation after administration of pergolide relative to bromocriptine. We 
hypothesized that pergolide, a mixed D1/D2 agonist, would improve WM in MTBI patients, 
presumably mediated by stimulation of D1 receptors.  
Our findings support this hypothesis. We saw significant interactions on several measures 
of n-back performance (0-back, 3-back, and mean-back), in which participants with MTBI 
showed relatively better performance on pergolide relative to bromocriptine, and healthy 
control participants showed the opposite. This pattern was seen in the context of poorer 
performance for MTBI patients relative to controls in general across conditions of the n-
back task, differences which reached statistical significance when on bromocriptine. 























































































































































































































































































group-by-drug interaction during the most challenging task condition (3-back>0-back 
contrast), in which the MTBI group showed increased activation in frontoparietal WM 
circuitry regions relative to controls when on pergolide relative to bromocriptine. Across 
participants there was a significant correlation between a cluster of activation in the left 
inferior frontal gyrus and 3-back task performance, such that greater activation on 
pergolide relative to bromocriptine correlated with improved task performance. In 
contrast, the two groups performed similarly on clinical neuropsychological measures, 
regardless of whether they were given pergolide or bromocriptine. 
The current results extend our understanding of the mechanism of cognitive complaints 
and dysfunction after MTBI by suggesting that WM difficulties after MTBI may be related 
to D1 receptor functioning. MTBI patients showed improved WM functioning and 
concomitant increases in activation of frontoparietal brain circuitry on pergolide, a mixed 
D1/D2 receptor agonist, relative to bromocriptine, a selective D2 receptor agonist, 
suggesting an important role for D1 receptors in improving performance after MTBI. Of 
particular interest is that an overall n-back performance indicator, the mean-back 
accuracy score, showed a significant (p=0.02) drug-by-diagnosis interaction. Examination 
of this interaction revealed better performance for the MTBI group on pergolide relative 
to bromocriptine, while healthy controls showed the opposite pattern. This builds upon 
our prior finding that MTBI patients showed poorer mean-back performance on 
bromocriptine relative to placebo, while controls showed stable to slightly improved 
performance.19 Examination of the differences observed in activation of brain regions 
within WM circuitry on these two agents is informative. Our earlier work suggested that 
bromocriptine facilitated selective recruitment of task-related processing resources in the 
healthy brain but not in the brains of individuals after MTBI. Across both groups improved 
task performance correlated with increased activation in the right middle frontal gyrus 
(Brodmann Area 9).19 In the current study treatment with pergolide resulted in increased 
activation in task-related neural circuitry during WM processing in MTBI patients relative 
to controls, including in the left inferior frontal gyrus (Brodmann Area 46). Again, 
activation correlated with task performance across both groups. This is particularly 
compelling as there is higher D1 receptor density in Brodmann Area 46 than in other 























































































































































































































































































While MTBI patients showed improved WM performance on pergolide relative to 
bromocriptine, healthy controls showed the opposite pattern. This may reflect the 
inverted-U dose-response effects noted for dopamine levels in prior work, where there has 
been found to be an optimal level of dopaminergic tone that promotes WM functioning, 
with both lower or higher levels resulting in lower functioning.6-9 In our cohort, controls 
may already have been functioning at an optimal baseline level in terms of D1 activity, 
such that administration of pergolide resulted in overall poorer performance relative to 
bromocriptine, whereas for MTBI patients, this medication could have helped to correct 
injury-related abnormalities in dopaminergic system functioning. Prior work has 
emphasized the particular sensitivity of the PFC to the dopaminergic environment, and the 
importance of considering not only an individual’s baseline level of dopaminergic 
functioning, but also the type of cognitive task being conducted.9 These complexities may 
explain the differential responses to varying pharmacological agents we observed in 
healthy and injured brains. In future work it will be informative to examine proxies of brain 
dopamine levels, for example using [11C]raclopride or [18F]fallypride PET, to better 
understand relationships between dopaminergic system functioning, cognitive 
performance, and brain activation. 
One possible mechanism that may account for enhanced performance on the n-back task 
in MTBI patients on pergolide may have to do with the role of dopamine in the 
improvement of neuronal signal-to-noise ratio (SNR). Dopamine is crucial in optimizing 
SNR of local cortical microcircuits in visual cortical networks,49, 50 principally due to D1- 
and D2-receptor-mediated effects on pyramidal and local circuit neurons, which mediate 
neuronal excitability and recurrent inhibition. Abnormal dopamine activity (i.e., increased 
dopamine receptor availability due to decreased levels of dopamine) has also been shown 
to be related to poorer WM performance in patients with schizophrenia.51 Yousif et al.52 
found that use of pergolide, but not cabergoline (a D2 agonist), maintained visual 
perceptual performance despite a TMS-induced reduction in SNR, in a dose-dependent 
manner. Together, these studies suggest that decreases in the ratio of D1/D2 signaling 
might be improved with medications such as antipsychotics, which target D2 receptors, or 
D1/D2 receptor agonists such as pergolide, by increasing cortical SNR and positively 























































































































































































































































































effects of dopamine on brain plasticity and learning, offer promise that medications such 
as pergolide could help improve rehabilitation efforts in individuals with TBI.  
The current findings also offer potential new insights into our prior work with other 
pharmacological agents. In a separate group of patients studied using the same design as 
in the current work we reported that a single administration of 2.0mg of guanfacine, an α-
2 adrenergic receptor agonist, resulted in improved WM performance in MTBI patients 
but not controls, with concomitant increased activation in WM circuitry. As noted above 
for D1 receptors, α-2 adrenergic receptors also have particularly high density in 
Brodmann Area 46.47, 48 We also examined the utility of cognitive-behavioral therapy in 
combination with methylphenidate, a norepinephrine and dopamine reuptake inhibitor, 
to treat cognitive concerns after TBI. We found post-treatment improvements in aspects 
of attention, episodic and working memory, and executive functioning,53 again with 
increased activation in WM circuitry,54 including in left Brodmann Area 10 and right 
Brodmann Area 45, the latter of which also shows relatively higher α-2 adrenergic 
receptor density. Taken together, these findings offer support for the hypothesis that 
alterations in dopaminergic and adrenergic system functioning can underlie cognitive 
problems after MTBI, and suggest that pharmacologic agents targeting dopamine D1 
and/or α-2 adrenergic receptors may be more beneficial than those targeting dopamine 
D2 receptors. 
There are important limitations to consider when interpreting the current findings.  This 
cohort had overall mild injury severity; these results therefore may not apply to those with 
moderate to severe injuries. We also intentionally excluded MTBI participants with 
significant medical and psychiatric disorders; therefore these results may not generalize to 
all individuals with MTBI. Further research in more heterogeneous cohorts with other 
comorbid conditions will be important to confirm these findings. Medication was 
administered as a single fixed dose, which may not be representative of the results of 
ongoing treatment, so direct clinical recommendations cannot be made as a result of this 
study. We detected differences in WM performance on the challenging n-back task, but 
not on other neuropsychological measures. This may indicate the need for more sensitive 
cognitive tasks to detect differences between MTBI patients and controls and/or changes 























































































































































































































































































comparison correlation; however, the moderate to large effect sizes that we observed for 
neuroimaging suggest that these findings may be clinically relevant. Further research in 
larger cohorts will be important to replicate these findings and explore additional research 
questions. For example, the current study cannot address differential effects of D1 and D2 
receptors forming heteromers with distinct signaling characteristics as compared to their 
constituent receptors.55   
Overall, the current results are most consistent with the conclusion that MTBI is associated 
with alterations in dopaminergic function that impact WM-related function and brain 
activation one month after MTBI, and that dopamine receptors differ with respect to 
effect of activity on cognition shortly after MTBI. Specifically, it appears that D1 
stimulation can enhance WM performance in the first 4-6 weeks after injury, despite our 
previous findings that a selective D2 agonist did not improve cognitive function. This 
finding may argue for renewed interest in identification of a selective D1 agonist for 
human use, such as the agent (PF-3628) recently characterized by Wang et al.,56 which 
showed evidence for an excitatory effect on WM-related dorsolateral prefrontal neuronal 
firing in primates, in an inverted-U dose-response fashion. Further exploration of other 
cognitive abilities, including episodic memory, will help clarify the role of various 
dopaminergic agents on other brain systems and circuits. In addition, future work should 
examine the effects that different dosing strategies, severity of injury, and the injury to 
treatment interval have on cognitive and brain outcomes. Finally, the literature also 
suggests a role of genotype on dopaminergic system functioning, cognitive outcome, and 
brain activation after TBI.13, 57-61 Interactions between genotype and dopaminergic system 
functioning (e.g., dopamine genetic risk score) should therefore also be further explored 
with regard to pharmacological treatment of cognitive symptoms after TBI. 
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 (N=15) p 
Age 33.6 ± 10.6 27.4 ± 10.7 0.11 
Education 16.0 ± 2.4 14.1 ± 2.0 0.02 
WRAT-3 Reading Standard 
Score 
110.2 ± 8.2 105.8 ± 10.9a 0.20 
WAIS-III Block Design 
Scaled Score 
12.5 ± 2.8 12.7 ± 3.3 0.81 
Maternal Education (years) 13.8 ± 2.3 13.9 ± 2.5 0.96 
Paternal Education (years) 15.5 ± 2.9 13.9 ± 2.6 0.12 
Sex    0.29 
   Male 7 (41.2%) 9 (60.0%)  
   Female 10 (58.8%) 6 (40.0%)  
Values are Mean + SD 
aN=14, one participant did not have a WRAT-3 Reading Score  
































































































































































































































































































Control vs. MTBI  




















Coding, Scaled Score 
63 13.4 ± 0.67 12.5 ± 0.72 0.27 12.8 ± 0.85 12.3 ± 0.79 0.62 0.81 0.66 0.73 0.29 0.68 
CVLT             
  Total Trials 1-5 64 57.2 ± 2.1 56.9 ± 2.7 0.94 55.0 ± 1.8 53.8 ± 1.7 0.73 0.98 0.77 0.86 0.85 0.75 
  Short Delay Free Recall 64 13.1 ± 0.59 11.9 ± 0.74 0.18 12.5 ± 0.53 12.5 ± 0.69 0.54 0.57 0.05 0.15 0.64 0.15 
  Long Delay Free Recall 64 13.5 ± 0.68 12.6 ± 0.75 0.22 12.3 ± 0.66 12.8 ± 0.74 0.27 0.85 0.24 0.59 0.97 0.09 
Trail Making Test (z-score)             
  Trial 2/Trails A 63 0.15 ± 0.22 0.31 ± 0.16 0.09 0.04 ± 0.19 0.19 ± 0.13 0.13 1.00 0.94 0.97 0.03 0.95 
  Trial 4/Trails B 62 0.42 ± 0.10 0.36 ± 0.07 0.83 0.20 ± 0.13 0.01 ± 0.13 0.47 0.22 0.05 0.07 0.72 0.48 
D-KEFS Color-Word 
Interference Test 
            
  Word Reading (secs) 63 20.2 ± 0.67 19.4 ± 0.58 0.24 21.9 ± 0.84 21.1 ± 0.9 0.41 0.26 0.20 0.19 0.18 0.84 
  Color Naming (secs) 63 24.8 ± 0.74 25.5 ± 0.48 0.78 26.9 ± 1.3 27.4 ± 1.2 0.91 0.20 0.23 0.19 0.80 0.91 
  Interference (secs) 63 44.9 ± 1.5 47.1 ± 1.7 0.32 45.4 ± 2.6 48.7 ± 2.8 0.09 0.88 0.59 0.72 0.07 0.54 



























































































































































































































































































Control vs. MTBI  
















criptine Pergolide Dx Drug 
Interactio
n 
COWAT (raw) 63 45.2 ± 1.8 45.4 ± 2.3 0.28 42.2 ± 2.9 41.1 ± 2.3 0.70 0.44 0.27 0.32 0.33 0.63 
PASAT (raw score/60)             
  Trial A 53 53.3 ± 2.1 47.8 ± 2.6 0.12 46.4 ± 3.3 46.2 ± 4.1 0.40 0.16 0.79 0.38 0.71 0.09 
  Trial B 51 49.9 ± 2.5 43.9 ± 2.9 0.27 40.8 ± 3.4 41.8 ± 4.2 0.49 0.09 0.33 0.17 0.85 0.20 
  Trial C 52 41.1 ± 2.6 37.1 ± 2.8 0.88 34.9 ± 3.6 38.3 ± 4.6 0.21 0.22 0.52 0.33 0.31 0.37 
  Trial D 50 27.9 ± 2.5 26.0 ± 2.3 0.79 26.0 ± 3.2 26.7 ± 3.3 0.61 0.56 0.69 0.60 0.59 0.82 
CPT             
  Simple Reaction Time, #     
  Correct 
64 29.8 ± 0.14 29.9 ± 0.06 0.35 29.3 ± 0.21 29.2 ± 0.30 0.77 0.52 0.08 0.14 0.68 0.37 
  Simple Reaction Time,  
  Reaction Time 
64 289 ± 17.6 295 ± 14.9 0.73 278 ± 11.8 281 ± 10.6 0.90 0.98 0.92 0.96 0.76 0.88 
  Vigilance, # Correct 63 29.7 ± 0.19 29.8 ± 0.14 0.57 29.9 ± 0.09 29.7 ± 0.13 0.62 0.52 0.83 0.80 0.98 0.43 
  Vigilance, Reaction Time 64 355 ± 21.5 371 ± 17.3 0.35 351 ± 15.9 350 ± 15.5 0.54 0.56 0.89 0.81 0.85 0.25 
  Distractibility, # Correct 63 28.5 ± 0.58 28.0 ± 0.81 0.84 28.5 ± 0.53 26.9 ± 1.1 0.21 0.97 0.42 0.65 0.32 0.41 
  Distractibility, Reaction    
  Time 
63 374 ± 22.3 413 ± 20.9 0.27 381 ± 14.6 398 ± 21.5 0.88 0.43 0.93 0.64 0.53 0.36 



























































































































































































































































































Control vs. MTBI  
















criptine Pergolide Dx Drug 
Interactio
n 
  Corrected 0-Back 64 97.5 ± 1.4 91.8 ± 3.1 0.30 83.1 ± 4.5 91.1 ± 3.0 0.04 0.01 0.72 0.15 0.44 0.02 
  Corrected 1-Back 64 93.5 ± 2.0 95.2 ± 1.7 0.54 89.4 ± 3.8 88.5 ± 2.9 0.88 0.43 0.16 0.19 0.77 0.57 
  Corrected 2-Back 64 89.7 ± 3.0 87.7 ± 3.1 0.63 73.9 ± 5.9 80.0 ± 5.6 0.16 0.09 0.62 0.22 0.50 0.16 
  Corrected 3-Back 64 80.5 ± 4.2 69.6 ± 3.0 0.09 62.5 ± 6.7 66.7 ± 3.5 0.31 0.02 0.74 0.11 0.68 <0.05 
  Mean-Back 64 90.3 ± 1.4 86.1 ± 1.7 0.17 77.2 ± 3.5 81.6 ± 2.3 0.05 <0.01 0.48 0.03 0.63 0.02 
  Mean-Back  
  without 0-Back 
64 87.9 ± 1.8 84.2 ± 1.8 0.25 75.3 ± 4.4 78.4 ± 3.2 0.18 0.02 0.40 0.08 0.85 0.07 
WAIS=Wechsler Adult Intelligence Scale, CVLT=California Verbal Learning Test, D-KEFS=Delis-Kaplan Executive Function System, 









































































































































































































































































































T Region description 
(for cluster peak) 
Effect size 
Cohen’s D (confidence interval) 
Increased Activation in MTBI Relative to HC on Pergolide Relative to Bromocriptine  
-20 -18 10 243 0.52 <0.01 4.68 Left Thalamus 0.81 (0.067, 1.556) 
38 -50 -44 455 0.06 0.001 4.39 Right Cerebellum 1.07 (0.303, 1.833) 
-40 40 4 530 0.03 <0.001 4.08 Left Inferior Frontal Gyrus BA 46 1.04 (0.279, 1.804) 
50 -46 42 126 0.98 <0.05 3.92 Right Inferior Parietal Lobule BA 40 0.66 (-0.075, 1.394) 
40 44 0 162 0.90 0.03 3.89 Right Inferior Frontal Gyrus BA 46 0.81 (0.064, 1.552) 
24 -6 44 144 0.95 0.04 3.87 Right Middle Frontal Gyrus BA 6 0.74 (0.003, 1.483) 
-16 -72 42 502 0.04 <0.001 3.61 Left Precuneus BA7 0.76 (0.019, 1.502) 
22 58 40 300 0.31 <0.01 3.42 Right Superior Frontal Gyrus BA 9 0.86 (0.111, 1.607) 
-34 0 34 164 0.89 0.03 3.38 Left Precentral Gyrus BA 6 0.36 (-0.363, 1.08) 
24 16 14 311 0.27 <0.01 3.26 Right Claustrum 0.76 (0.022, 1.505) 
Increased Activation in HC Relative to MTBI on Pergolide Relative to Bromocriptine  

























































































































































































































































































Figure 1. Prolactin time trends by drug condition (placebo, bromocriptine, pergolide) and 
participant group (Mild Traumatic Brain Injury = MTBI, Healthy Control = Control). The 
targeted times for beginning MRI and neuropsychological (NP) testing are noted. Prolactin 
suppression is evident during the scan and cognitive assessment time periods for both 
bromocriptine and pergolide relative to placebo, but does not differ by drug or group (see 


























































































































































































































































































Figure 2. A. Average activation during the visual-verbal n-back task for both groups for 
both study visits (3-back>0-back contrast, p = 0.05), used as an explicit mask for statistical 
analyses. B. Increased activation in working memory circuitry during the visual-verbal n-
back task (3-back>0-back contrast) for mild traumatic brain injury relative to healthy 
control group on pergolide relative to bromocriptine (pcrit = .01, cluster-level puncorrected < 
0.05). C. Correlation of change in left inferior frontal gyrus activation with change in 3-back 
performance across all participants. 
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